Treatment goals and QOL in a survey of patients with ER+/HER2- mBC

Anonymous survey about discontinuing HER2 treatmentsПодробнее

HER2-low mBC patients report preserved QOL with trastuzumab deruxtecanПодробнее

Research Update for ER-Positive MBC | 2022-2023 EMBRACE MBC Virtual Forum SeriesПодробнее

2021 ASCO Direct St. Louis | Metastatic Breast Cancer Summary | Dr. Jane MeiselПодробнее

Research Update for HER2-Positive MBC | 2022-2023 EMBRACE MBC Virtual Forum SeriesПодробнее

Living long term with MBC: Making treatment decisionsПодробнее

Elacestrant in ER+/HER2- mBC: Overview of the EMERALD subgroup analysisПодробнее

Sacituzumab govitecan continues to improve OS for ET-resistant HR+/HER2-mBC, and QoL updateПодробнее

HER2-Positive MBC Research Update | 2024-2025 EMBRACE MBC Virtual Forum SeriesПодробнее

Treating ER+/HER2-low metastatic breast cancer, 2L and beyondПодробнее

Optimisation of Treatment Selection & Sequencing Decisions in ER+/HER2- Breast CancerПодробнее

What's New for the Patient With ER+/HER2- MBC Progressing on CDK 4/6 Inhibitor Therapy? Expert Pe...Подробнее

HER2 Positive Breast Cancer: What's New in Treatment and Research at MBC Patient Forum 2019Подробнее

2020 EMBRACE Metastatic Breast Cancer Virtual Forum Series | Research Update for HER2-Positive MBCПодробнее

Research Update for HER2-Positive MBC | 2023-2024 EMBRACE MBC Virtual Forum SeriesПодробнее

ASCO 2022: Metastatic Breast Cancer Drug Therapy RecapПодробнее

ELAINE 1: LAS vs fulv in la ER+/HER2- mBC ESR1m + disease progression on AI and CDK4/6i inhibitorsПодробнее

Changing Treatment Landscape In HR+HER2 aBCПодробнее

Optimizing Treatment Options for HER2+/ ER+ Breast Cancer using Models of Endocrine ResistanceПодробнее